L & S Advisors Has Lifted Baidu (Adr) (BIDU) Position By $816,088; Hudson Bay Capital Management LP Has Decreased Neogenomics New (NEO) Position

January 14, 2018 - By Migdalia James

L & S Advisors Inc increased Baidu Inc (Adr) (BIDU) stake by 53.9% reported in 2017Q3 SEC filing. L & S Advisors Inc acquired 3,304 shares as Baidu Inc (Adr) (BIDU)’s stock rose 1.94%. The L & S Advisors Inc holds 9,434 shares with $2.34M value, up from 6,130 last quarter. Baidu Inc (Adr) now has $87.86 billion valuation. The stock increased 1.13% or $2.82 during the last trading session, reaching $253.04. About 3.04 million shares traded or 19.92% up from the average. Baidu, Inc. (NASDAQ:BIDU) has risen 12.02% since January 14, 2017 and is uptrending. It has underperformed by 4.68% the S&P500.

Hudson Bay Capital Management Lp decreased Neogenomics Inc New (NEO) stake by 15.38% reported in 2017Q3 SEC filing. Hudson Bay Capital Management Lp sold 30,000 shares as Neogenomics Inc New (NEO)’s stock declined 8.15%. The Hudson Bay Capital Management Lp holds 165,000 shares with $1.84M value, down from 195,000 last quarter. Neogenomics Inc New now has $667.40 million valuation. The stock decreased 2.47% or $0.21 during the last trading session, reaching $8.3. About 469,360 shares traded or 36.39% up from the average. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since January 14, 2017 and is downtrending. It has underperformed by 30.16% the S&P500.




L & S Advisors Inc decreased Texas Instruments Inc (NASDAQ:TXN) stake by 52,670 shares to 13,458 valued at $1.21M in 2017Q3. It also reduced Newell Brands Inc (NYSE:NWL) stake by 113,179 shares and now owns 29,580 shares. Becton Dickinson & Co (NYSE:BDX) was reduced too.

Among 24 analysts covering Baidu (NASDAQ:BIDU), 9 have Buy rating, 4 Sell and 11 Hold. Therefore 38% are positive. Baidu had 56 analyst reports since July 28, 2015 according to SRatingsIntel. As per Tuesday, July 28, the company rating was downgraded by KeyBanc Capital Markets. The stock of Baidu, Inc. (NASDAQ:BIDU) has “Sell” rating given on Friday, July 14 by Bernstein. The firm earned “Buy” rating on Friday, July 28 by Macquarie Research. The firm has “Buy” rating given on Monday, April 25 by Jefferies. The company was downgraded on Wednesday, September 28 by Deutsche Bank. The firm has “Hold” rating by Deutsche Bank given on Wednesday, September 9. Jefferies upgraded the shares of BIDU in report on Monday, August 31 to “Buy” rating. The firm has “Neutral” rating by Nomura given on Friday, January 22. Cantor Fitzgerald initiated the stock with “Underweight” rating in Monday, December 19 report. Credit Agricole downgraded Baidu, Inc. (NASDAQ:BIDU) on Tuesday, July 28 to “Underperform” rating.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Overweight” rating by First Analysis on Tuesday, October 4. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, May 26 report. The stock has “Buy” rating by Roth Capital on Wednesday, May 11. As per Monday, September 11, the company rating was downgraded by BTIG Research. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Neutral” rating by BTIG Research on Wednesday, July 27. The company was initiated on Friday, March 11 by Benchmark. Cantor Fitzgerald initiated the stock with “Overweight” rating in Thursday, December 15 report. Roth Capital maintained the shares of NEO in report on Thursday, September 3 with “Buy” rating. The firm has “Sell” rating given on Wednesday, November 16 by Axiom Capital. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by TH Capital on Monday, October 26.

Investors sentiment increased to 1.28 in 2017 Q3. Its up 0.10, from 1.18 in 2017Q2. It increased, as 11 investors sold NEO shares while 36 reduced holdings. 21 funds opened positions while 39 raised stakes. 62.50 million shares or 3.94% more from 60.13 million shares in 2017Q2 were reported. Legacy Cap Inc reported 54,800 shares. Raymond James, Florida-based fund reported 10,485 shares. Hightower Advisors Lc holds 252,815 shares. Guggenheim Ltd Liability Corporation owns 26,919 shares. Price T Rowe Assoc Incorporated Md owns 14,746 shares. First Light Asset Mgmt Limited Liability Company owns 2.41 million shares for 8.49% of their portfolio. Citigroup Inc owns 16,633 shares or 0% of their US portfolio. Portfolio Solutions Lc has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Bard Inc invested 1.33% in NeoGenomics, Inc. (NASDAQ:NEO). Falcon Point Lc owns 2.03% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 1.61M shares. Peak6 LP stated it has 53,217 shares. Matarin Ltd Com invested in 0.08% or 80,233 shares. Emerald Mutual Fund Advisers accumulated 1.12 million shares. Wells Fargo Mn owns 89,392 shares for 0% of their portfolio. Deutsche Bankshares Ag invested in 61,627 shares.

Hudson Bay Capital Management Lp increased Biomarin Pharmaceutical Inc (NASDAQ:BMRN) stake by 89,500 shares to 185,500 valued at $17.26M in 2017Q3. It also upped Northrop Grumman Stk (NYSE:NOC) stake by 5,272 shares and now owns 15,272 shares. Commercehub Inc Ser C was raised too.

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on February, 28. They expect $0.02 EPS, down 33.33% or $0.01 from last year’s $0.03 per share. NEO’s profit will be $1.61M for 103.75 P/E if the $0.02 EPS becomes a reality. After $-0.02 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -200.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts